Danaher Corporation $DHR Stock Holdings Lessened by Perbak Capital Partners LLP

Key Points

• Perbak Capital Partners LLP reduced its stake in Danaher Corporation by 68.4% in the first quarter, owning 1,552 shares worth $318,000 after selling 3,359 shares.
• Danaher reported earnings of $1.80 per share for the latest quarter, exceeding analysts' expectations, with quarterly revenue rising 3.4% year-over-year to $5.94 billion.
• Seventeen analysts have rated Danaher as a "Buy," while the average price target for the stock is currently set at $247.61.

Perbak Capital Partners LLP trimmed its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 68.4% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,552 shares of the conglomerate's stock after selling 3,359 shares during the period. Perbak Capital Partners LLP's holdings in Danaher were worth $318,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of DHR. GHP Investment Advisors Inc. lifted its stake in shares of Danaher by 396.0% during the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after buying an additional 99 shares during the period. Heck Capital Advisors LLC purchased a new position in shares of Danaher during the fourth quarter valued at approximately $27,000. Sierra Ocean LLC lifted its stake in shares of Danaher by 116.9% during the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after buying an additional 76 shares during the period. Smallwood Wealth Investment Management LLC purchased a new position in shares of Danaher during the first quarter valued at approximately $31,000. Finally, Dunhill Financial LLC raised its stake in Danaher by 68.4% during the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after purchasing an additional 67 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Trading Up 0.6%

Shares of Danaher stock traded up $1.29 during trading hours on Friday, hitting $200.32. The company's stock had a trading volume of 2,837,584 shares, compared to its average volume of 2,859,442. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90. The business has a fifty day moving average of $201.93 and a 200 day moving average of $199.41. The company has a market capitalization of $143.44 billion, a PE ratio of 42.62, a P/E/G ratio of 2.78 and a beta of 0.75. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analyst estimates of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 11.10% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research note on Tuesday. UBS Group cut their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reaffirmed a "buy" rating and set a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Finally, Wells Fargo & Company cut their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.